GGF-213: Potential Drug Targets (G2961)

Target Name: GTF2E2

NCBI ID: G2961

GGF-213: Potential Drug Targets

GGF-213 (GGF-213) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Growth factors and growth factor-like receptor (GFGFR) family, which is a subfamily of the TGF-β receptor signaling pathway. GGF-213 has been shown to play a role in several physiological processes in the body, including cell survival, proliferation, and angiogenesis.

One of the unique features of GGF-213 is its ability to interact with the transcription factor PDGF-BB. This interaction allows GGF-213 to regulate the activity of other genes, including those involved in cell adhesion, migration, and differentiation. Additionally, GGF-213 has been shown to play a role in the regulation of the blood-brain barrier, which is a critical barrier that separates the brain from the surrounding blood vessels and is responsible for maintaining the integrity of the brain's microenvironment.

GGF-213 has also been shown to be involved in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GGF-213 has been shown to promote the growth and survival of cancer cells, and it has also been shown to contribute to the development and progression of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Due to its involvement in several diseases and conditions, GGF-213 has been identified as a potential drug target. Researchers have been studying the potential therapeutic benefits of targeting GGF-213, and several compounds have been shown to be effective in treating conditions associated with GGF-213 activity.

One of the compounds that has been shown to be effective in treating conditions associated with GGF-213 activity is rapamycin. Rapamycin is an inhibitor of the mTOR pathway, which is a critical pathway involved in cell growth, proliferation, and angiogenesis. By inhibiting the activity of the mTOR pathway, rapamycin has been shown to reduce the activity of GGF-213 and prevent its ability to promote the growth and survival of cancer cells.

Another compound that has been shown to be effective in treating conditions associated with GGF-213 activity is curcumin. Curcumin is a compound that is derived from the leaves of the curcuma plant, and it has been shown to have anti-inflammatory and antioxidant properties. By inhibiting the activity of several different signaling pathways, including the TGF-β pathway, curcumin has been shown to reduce the activity of GGF-213 and prevent its contribution to the development and progression of several diseases.

In conclusion, GGF-213 is a protein that is involved in several physiological processes in the body, including cell survival, proliferation, and angiogenesis. Its interaction with the transcription factor PDGF-BB and its ability to regulate the blood-brain barrier make it a potential drug target. Several compounds, including rapamycin and curcumin, have been shown to be effective in treating conditions associated with GGF-213 activity. Further research is needed to fully understand the role of GGF-213 in the development and treatment of various diseases.

Protein Name: General Transcription Factor IIE Subunit 2

Functions: Recruits TFIIH to the initiation complex and stimulates the RNA polymerase II C-terminal domain kinase and DNA-dependent ATPase activities of TFIIH. Both TFIIH and TFIIE are required for promoter clearance by RNA polymerase

More Common Targets